"Esophagogastric Junction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The area covering the terminal portion of ESOPHAGUS and the beginning of STOMACH at the cardiac orifice.
Descriptor ID |
D004943
|
MeSH Number(s) |
A03.556.875.500.414 A03.556.875.875.330
|
Concept/Terms |
Esophagogastric Junction- Esophagogastric Junction
- Junction, Esophagogastric
- Gastroesophageal Junction
- Gastroesophageal Junctions
- Junction, Gastroesophageal
- Junctions, Gastroesophageal
|
Below are MeSH descriptors whose meaning is more general than "Esophagogastric Junction".
Below are MeSH descriptors whose meaning is more specific than "Esophagogastric Junction".
This graph shows the total number of publications written about "Esophagogastric Junction" by people in this website by year, and whether "Esophagogastric Junction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 1 | 0 | 1 |
2001 | 5 | 0 | 5 |
2002 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2004 | 6 | 2 | 8 |
2005 | 1 | 2 | 3 |
2006 | 6 | 3 | 9 |
2007 | 7 | 1 | 8 |
2008 | 5 | 2 | 7 |
2009 | 3 | 1 | 4 |
2010 | 6 | 1 | 7 |
2011 | 5 | 0 | 5 |
2012 | 7 | 3 | 10 |
2013 | 5 | 0 | 5 |
2014 | 4 | 3 | 7 |
2015 | 7 | 4 | 11 |
2016 | 11 | 7 | 18 |
2017 | 9 | 4 | 13 |
2018 | 5 | 0 | 5 |
2019 | 6 | 2 | 8 |
2020 | 4 | 2 | 6 |
2021 | 6 | 5 | 11 |
2022 | 0 | 7 | 7 |
2023 | 0 | 14 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Esophagogastric Junction" by people in Profiles.
-
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. Br J Cancer. 2024 02; 130(3):476-482.
-
The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. Pract Radiat Oncol. 2024 Jan-Feb; 14(1):28-46.
-
The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. Ann Thorac Surg. 2024 Jan; 117(1):15-32.
-
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. J Clin Oncol. 2023 Dec 10; 41(35):5388-5399.
-
Trans-pacific multicenter collaborative study of minimally invasive proximal versus total gastrectomy for proximal gastric and gastroesophageal junction cancers. BMC Surg. 2023 Sep 01; 23(1):262.
-
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 08; 29(8):2133-2141.
-
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma. J Clin Oncol. 2023 10 01; 41(28):4535-4547.
-
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 07; 24(7):744-756.
-
Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 Feb; 117(2):320-326.
-
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 05 20; 401(10389):1655-1668.